High Fructose Diet, the Gut Microbiome, and Metabolic Health
Americans commonly consume excess amounts of dietary fructose. Added fructose has been
shown to have an adverse impact on metabolic health, including increased insulin
resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary
fructose and m...
Age: 25 - 45 years
Gender: All
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or
atezolizumab alone, as first-line treatment in participants with unresectable, locally
advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
This project investigates whether exposure to the World Trade Center Attack is a risk factor
for liver injury.
Age: 55 - 80 years
Gender: All
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747)
can lead to histological improvement in fibrosis with no worsening of NASH in adults with
compensated cirrhosis due to NASH.
Age: 18 years - 66+
Gender: All